510(k) Report

510(k) · Cleared

Cleared

Evok 900 Series Hearing Aid/Tinnitus Masker Option Device

K093715510(k) AbbreviatedCleared Dec 22, 2010386-day reviewClass II21 CFR 874.3400

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Magnatone Hearing Aid Corp. Dba Persona Medical · KLW Masker, Tinnitus

Cleared on Dec 22, 2010 as substantially equivalent to K974751 (General Hearing Instruments, Inc., 1998) and 1 other predicate after a 386-day review. Its family tree reaches back 4 generations to 1998.

Decided
Dec 22, 2010
Review
386 days
Class
Class II
Product code
KLW
Recalls
None
Predicates
2

Its longest line of descent runs back 4 generations to K974501 (1998). 7 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 4 generations backK974501 Digital Tinnitus Masking SystemPetroff Audio Technologies · 1998
  2. 3 generations backK030791 Anmp (Acoustic Neuro Modulation Protocol)Tinnitech, Ltd. · 2003
  3. 2 generations backK040330 QuiescenceSpectral Visualization & Development, Inc. · 2004
  4. 1 generation backK073636 Tinnitus Sound Generator ModuleGn Resound A/S · 2008
  5. This deviceK093715 Evok 900 Series Hearing Aid/Tinnitus Masker Option DeviceMagnatone Hearing Aid Corp. Dba Persona Medical · 2010
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4K974501Digital Tinnitus Masking SystemPetroff Audio Technologies1998—
−3K030791Anmp (Acoustic Neuro Modulation Protocol)Tinnitech, Ltd.2003—
−2K040330QuiescenceSpectral Visualization & Development, Inc.2004—
−1K073636Tinnitus Sound Generator ModuleGn Resound A/S2008—
0 (this device)K093715Evok 900 Series Hearing Aid/Tinnitus Masker Option DeviceMagnatone Hearing Aid Corp. Dba Persona Medical2010—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199810
200120
FIG. 1 — Lineage of K093715, 1998–2010Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KLW? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new KLW device

  1. #1 K260413 Levo Gen 2 Tinnitus Therapy Systemscore 11.8 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (3)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K974751Tranquil Tri-OE, Tranquil Tri-Coe, Tranquil Tri-Cic
Summary page 2
…ation Name: Tinnitus Masker/Hearing Aid Regulatory Class: Class If/Class I Product Code: KLW 5 10(k) Number: K974751 Manufacturer: GN Resound 8001 Bloomington Freeway,…
General Hearing Instruments, Inc.1998—
*K073636Tinnitus Sound Generator Module
Summary page 2
…lation Name: Tinnitus Masker/Hearing Aid Regulatory Class: Class IIClass I Product Code: KLW 5 10(k) Number: K073636 Device Description: Our devices are a combination of a hearing aid and a tinnitus masker in the same instrument.…
Gn Resound A/S2008—
*—GN Resound Live TS BTE, OTE and RIB (RIC) products
Named without a submission number
—

Also cleared against K974751: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 12 years and passes through 5 companies; a new generation was cleared every 3.9 years on median.
  • None of the 7 ancestors has a recall.
  • 2 other devices also cite its predicate K974751.

How does its category compare?

All KLW devices

KLW Masker, Tinnitus: FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.

FDA decisions per year · KLW

1in 2024

2007: 22008: 22009: 22010: 12011: 42012: 12013: 42014: 42015: 42016: 32017: 22018: 22020: 22023: 32024: 12026 (partial year): 2
2007high 4 (2011) · low 0 (2019)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KLW

261in 2023

2011: 58 days median2013: 150 days median2014: 164 days median2015: 107 days median2016: 114 days median2023: 261 days median
2007high 261 (2023) · low 58 (2011)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · KLW

No recall names KLW since 2007.

Adverse event reports per year · KLW

4in 2015

2007: 12009: 12010: 12011: 12012: 12015: 4
2007high 4 (2015) · low 0 (2008)2025

MAUDE reports naming product code KLW, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—01
20082—00
20092—01
20101—01
201145801
20121—01
2013415000
2014416400
2015410704
2016311400
20172—00
20182—00
20190—00
20202—00
20210—00
20220—00
2023326100
20241—00
20250—00
20262—0—

What is it indicated for?

The Evok series is designed for use in sound therapy for tinnitus retraining therapy, masking, or other recognized forms of tinnitus treatment. Sound therapy should be used in concert with counseling from a physician, an audiologist or other qualified tinnitus specialists. The target population for this product is primarily the adult population 18 years of age and older. The target group for this product includes individuals reporting tinnitus who can…

Read the full statement (226 words)

The Evok series is designed for use in sound therapy for tinnitus retraining therapy, masking, or other recognized forms of tinnitus treatment. Sound therapy should be used in concert with counseling from a physician, an audiologist or other qualified tinnitus specialists.

The target population for this product is primarily the adult population 18 years of age and older. The target group for this product includes individuals reporting tinnitus who can also benefit from an air conduction hearing aid.

NOTE: The Evok 900 series Tinnitus Masker Devices are targeted primarily to the adult population over 18 years old. Our User Guide does state this but it also has a statement that reads; "a child with a hearing loss should be directed to an Audiologist for evaluation and rehabilitation". This is not meant to be a contradiction considering the user guide is generic in the general information supplied to the end user.

As part of a Tinnitus Management Program, we suggest the following recommendations applicable to clinical settings for all the devices listed above;

The Tinnitus Management treatment should include evaluation and recommendations done by a qualified audiologist, otorhinolaryngologists or other licensed hearing healthcare professional. Since tinnitus can be associated with a number of auditory conditions, the audiologic evaluation can yield extensive information regarding the possible cause for the tinnitus and options for a successful Tinnitus Management treatment.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K093715: Evok 900 Series Hearing Aid/Tinnitus Masker Option Device.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K093715

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026